natgillin/translations-raw huggingface dataset:
Paragraph 1 shall also apply to subsequent verifications of declarations of origin.
Tudi za naknadna preverjanja izjav o poreklu se uporablja odstavek 1.
Where the verification procedure referred to in Article 30 or where information available to the competent authorities of the Community indicates that the provisions of this Chapter are being contravened, the said authorities shall request the Russian Federation to carry out appropriate enquiries or arrange for such enquiries to be carried out concerning operations which are or appear to be in contravention of the provisions of this Chapter.
Če postopek preverjanja iz člena 30 ali informacije, ki so na razpolago pristojnim organom Skupnosti, pokažejo, da se določbe iz tega poglavja kršijo, navedeni organi od Ruske federacije zahtevajo, da opravi ustrezne poizvedbe ali poskrbi, da se izvedejo take poizvedbe v zvezi s poslovanjem, ki je ali se zdi, da je, v nasprotju z določbami tega poglavja.
In pursuance of the action taken in accordance with the provisions of this Chapter, the competent authorities of the Community may exchange any information with the competent authorities of the Russian Federation which is considered to be of use in preventing the contravention of the provisions of this Chapter.
Na podlagi ukrepov v skladu določbami tega poglavja lahko pristojni organi Skupnosti izmenjajo s pristojnimi organi Ruske federacije vse podatke, ki veljajo za koristne pri preprečevanju kršitev določb tega poglavja.
Regulation (EC) No 2267/2004 is hereby repealed.
Uredba (ES) št. 2267/2004 se razveljavi.
OJ L 395, 31.12.2004, p. 38.
UL L 395, 31.12.2004, str. 38.
SB Long products
SB Podolgovati izdelki
Other longs
Drugi podolgovati izdelki
Authority responsible for issue (name, address and telephone No)
Pristojni organ izdaje (ime, naslov in telefonska št.)
Declarant/representative as applicable (name and full address)
Deklarant/zastopnik (po potrebi) (ime in polni naslov)
Country of origin (and geonomenclature code)
Država porekla (in šifra po geonomenklaturi)
Country of consignment (and geonomenclature code)
Država odpreme (in šifra po geonomenklaturi)
Security/guarantee (as applicable)
Jamstvo/garancija (po potrebi)
Indicate the quantity available in part 1 of column 17 and the quantity attributed in part 2 thereof
Razpoložljivo količino navedite v prvem delu stolpca 17 in odpisano količino v drugem delu stolpca 17.
Customs document (form and number) or extract No and date of attribution
Carinski dokument (vrsta in številka) ali številka delnega dovoljenja in datum odpisa
Name, Member State, stamp and signature of the attributing authority
Ime, država članica, žig in podpis organa odpisa
Copy for the issuing authority
Izvod za pristojni organ izdaje
Flat-rolled products
Ploščato valjani izdelki
Alloyed cold-rolled and coated sheets
Legirane hladno valjane in prevlečene pločevine
Council Regulation (EC) No 1900/2005
Uredba Sveta (ES) št. 1900/2005
amending Regulation (EC) No 382/2001 concerning the implementation of projects promoting cooperation and commercial relations between the European Union and the industrialised countries of North America, the Far East and Australasia
o spremembi Uredbe (ES) št. 382/2001 o izvajanju projektov spodbujanja sodelovanja ter trgovinskih odnosov med Evropsko unijo in industrializiranimi državami Severne Amerike, Daljnega vzhoda, Avstralije in Oceanije
Having regard to the Treaty establishing the European Community, and in particular Article 133 and 181a thereof,
ob upoštevanju Pogodbe o ustanovitvi Evropske skupnosti in zlasti členov 133 in 181a Pogodbe,
Regulation (EC) No 382/2001 [2] provides a legal framework for the enhancement of cooperation and commercial relations with the industrialised countries of North America, the Far East and Australasia until 31 December 2005.
Uredba (ES) št. 382/2001 [2] do 31. decembra 2005 določa pravni okvir za spodbujanje sodelovanja in trgovinskih odnosov z industrializiranimi državami Severne Amerike, Daljnega vzhoda, Avstralije in Oceanije.
Certain future aspects of the legal framework for the Community intervention in the area of external relations, including the promotion of cooperation and economic relations with industrialised countries, during the next period of Financial Perspectives (2007-2013) are yet to be determined.
Nekatere vidike pravnega okvira za ukrepanje Skupnosti na področju zunanjih odnosov, vključno s spodbujanjem sodelovanja in gospodarskih odnosov z industrializiranimi državami, je treba za obdobje naslednje finančne perspektive (2007–2013) šele določiti.
At the earliest, such new legal framework may apply from 1 January 2007.
Ta nov pravni okvir ne bo začel veljati pred 1. januarjem 2007.
As it is crucial to ensure continuity in cooperation activities with industrialised countries, it is therefore necessary to avoid the potential absence of a legal basis for those activities between the current expiry date of Regulation (EC) No 382/2001 and the date from which a new legal framework may apply.
Ker je zagotavljanje neprekinjenega sodelovanja z industrializiranimi državami bistvenega pomena, je treba zagotoviti, da bo med trenutno določenim datumom prenehanja veljavnosti Uredbe (ES) št. 382/2001 in datumom, od katerega se bo lahko uporabljal nov pravni okvir, obstajala pravna podlaga za te dejavnosti.
Extending the validity of Regulation (EC) No 382/2001 for an appropriate period will make it possible to bridge any potential gap in the legal framework governing cooperation with industrialised countries.
Podaljšanje veljavnosti Uredbe (ES) št. 382/2001 za ustrezno obdobje bo omogočilo zapolnitev morebitne vrzeli v pravnem okviru, ki ureja sodelovanje z industrializiranimi državami.
The extension in time of Regulation (EC) No 382/2001 is all the more justified as the evaluation carried out in 2004 of the projects and programmes financed under that Regulation established their effectiveness and called for their continuation with due attention to be paid to coordination of the supported activities within and between the partner countries concerned.
Podaljšanje veljavnosti Uredbe (ES) št. 382/2001 je toliko bolj upravičeno, ker je bila v oceni iz leta 2004 o projektih in programih, financiranih v okviru te uredbe, ugotovljena njihova učinkovitost in zahtevano njihovo nadaljevanje, pri čem je treba ustrezno pozornost posvetiti usklajevanju podpornih dejavnosti v in med zadevnimi državami partnericami.
The second subparagraph of Article 114(1) of Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities [3] provides for the possibility of awarding grants to natural persons, by way of exception, when provided for by the basic act.
Drugi pododstavek člena 114(1) Uredbe Sveta (ES, Euratom) št. 1605/2002 z dne 25. junija 2002 o finančni uredbi, ki se uporablja za splošni proračun Evropskih skupnosti [3], določa, da lahko donacije izjemoma prejmejo tudi fizične osebe, če to določa temeljni akt.
Such situations arise regularly in connection with the implementation of the Executive Training Programmes in Japan and in Korea and may occasionally arise in the case of other cooperation activities with industrialised countries, in particular in the framework of education cooperation or people-to-people exchanges.
Takšni primeri se redno pojavljajo v zvezi z izvajanjem programov usposabljanja vodilnih delavcev na Japonskem in v Koreji ter občasno v primeru drugih dejavnosti sodelovanja z industrializiranimi državami, predvsem v okviru sodelovanja na področju izobraževanja ali neposrednih izmenjav.
Regulation (EC) No 382/2001 should therefore be amended accordingly,
Uredbo (ES) št. 382/2001 je zato treba ustrezno spremeniti –
Regulation (EC) No 382/2001 is hereby amended as follows:
Uredba (ES) št. 382/2001 se spremeni:
In Article 5, the following paragraph shall be added:
V členu 5 se doda naslednji odstavek:
‘When appropriate, in particular in the case of education and training projects, or other similar projects from which individuals may benefit, Community support may take the form of grants to natural persons.
„Če je to primerno, predvsem pri projektih za izobraževanje in usposabljanje ali drugih podobnih projektih, ki so namenjeni posameznikom, ima podpora Skupnosti lahko obliko donacij fizičnim osebam.
These grants may take the form of scholarships.’.
Te donacije so lahko podeljene v obliki štipendij.“;
In Article 7, the following paragraph shall be added:
V členu 7 se doda naslednji odstavek:
‘To this effect, Community support may take the form of grants to natural persons.
„V ta namen ima lahko podpora Skupnosti obliko donacij fizičnim osebam.
In Article 13, the second paragraph shall be replaced by the following:
V členu 13 se drugi odstavek nadomesti z naslednjim:
‘It shall expire on 31 December 2007.’.
„Velja do 31. decembra 2007.“.
Opinion of 23.6.2005 (not yet published in the Official Journal).
Mnenje z dne 23.6.2005 (še ni objavljeno v Uradnem listu).
OJ L 57, 27.2.2001, p. 10.
UL L 57, 27.2.2001, str. 10.
Commission Regulation (EC) No 1901/2005
Uredba Komisije (ES) št. 1901/2005
This Regulation shall enter into force on 22 November 2005.
Ta uredba začne veljati 22. novembra 2005.
to Commission Regulation of 21 November 2005 establishing the standard import values for determining the entry price of certain fruit and vegetables
k Uredbi Komisije z dne 21. novembra 2005 o določitvi pavšalnih uvoznih vrednosti za določanje vhodne cene nekaterega sadja in zelenjave
Commission Regulation (EC) No 1902/2005
Uredba Komisije (ES) št. 1902/2005
establishing a prohibition of fishing for anglerfish in ICES zones VII by vessels flying the flag of Spain
o prepovedi ribolova na morsko spako v območju ICES VII s plovili, ki plujejo pod špansko zastavo
Commission Regulation (EC) No 1903/2005
Uredba Komisije (ES) št. 1903/2005
establishing a prohibition of fishing for mackerel in ICES zone IIa (non-EC waters), Vb (EC waters), VI, VII, VIIIa, b, d, e, XII, XIV by vessels flying the flag of France
o prepovedi ribolova na skušo na območjih II a (ne-ES vode), V b (vode ES), VI, VII, VIII a, b, d, e, XII, XIV s plovili, ki plujejo pod francosko zastavo
Mackerel (Scomber scombrus)
skuša (Scomber scombrus)
IIa (non-EC waters), Vb (EC waters), VI, VII, VIIIa, b, d, e, XII, XIV
IIa (ne-ES vode), V b (vode ES), VI, VII, VIII a, b, d, e, XII, XIV
Commission Regulation (EC) No 1904/2005
Uredba Komisije (ES) št. 1904/2005
The Community producer and import prices for uniflorous (bloom) carnations, multiflorous (spray) carnations, large-flowered roses and small-flowered roses as referred to in Article 1 of Regulation (EEC) No 4088/87 shall be as set out in the Annex hereto for the period from 23 November to 6 December 2005.
Proizvodne in uvozne cene Skupnosti za enocvetne (navadne) nageljne, mnogocvetne (spray) nageljne, velecvetne vrtnice in drobnocvetne vrtnice iz člena 1 Uredbe (EGS) št. 4088/87 so določene v Prilogi sedanje uredbe za obdobje od 23. novembra do 6. decembra 2005.
Period from 23 November to 6 December 2005
Obdobje: od 23. novembra do 6. decembra 2005
Council Regulation (EC) No 1905/2005
Uredba Sveta (ES) št. 1905/2005
amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency
o spremembi Uredbe (ES) št. 297/95 o pristojbinah, ki se plačujejo Evropski agenciji za zdravila
Having regard to Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products [1], and in particular Article 12 thereof,
ob upoštevanju Uredbe Sveta (ES) št. 297/95 z dne 10. februarja 1995 o pristojbinah, ki se plačujejo Evropski agenciji za zdravila [1], in zlasti člena 12 Uredbe,
Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation, supervision and surveillance of medicinal products for human and veterinary use and establishing a European Medicines Agency [3], stipulates that the revenue of the European Medicines Agency (hereinafter referred to as the Agency) shall consist of a contribution from the Community and fees paid by undertakings for obtaining and maintaining Community marketing authorisations and for other services provided by the Agency.
Člen 67(3) Uredbe Evropskega parlamenta in Sveta (ES) št. 726/2004 z dne 31. marca 2004 o postopkih Skupnosti za pridobitev dovoljenja za promet in nadzor zdravil za humano in veterinarsko uporabo ter o ustanovitvi Evropske agencije za zdravila [3] določa, da bodo prihodki Evropske agencije za zdravila (v nadaljevanju „Agencija“) sestavljeni iz prispevka Skupnosti in pristojbin, ki jih plačajo podjetja za pridobitev ter ohranitev dovoljenj za promet v Skupnosti ter za druge storitve, ki jih zagotavlja Agencija.
Regulation (EC) No 726/2004 also provides for new tasks for the Agency.
Uredba (ES) št. 726/2004 določa tudi nove naloge Agencije.
Furthermore, the existing tasks have also been changed following amendments to Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products [4] and to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [5].
Poleg tega so bile spremenjene obstoječe naloge ob upoštevanju sprememb Direktive Evropskega parlamenta in Sveta 2001/82/ES z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v veterinarski medicini [4] in Direktive Evropskega parlamenta in Sveta 2001/83/ES z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v humani medicini [5].
In view of the experience gained since 1995, it is appropriate to maintain the general principles and overall structure of the fees, as well as the main operational and procedural provisions established by Regulation (EC) No 297/95.
Glede na izkušnje, pridobljene v obdobju od leta 1995, je primerno ohraniti splošna načela in splošno strukturo pristojbin, kot tudi glavne operativne ter postopkovne določbe, ki so bile uvedene z Uredbo (ES) št. 297/95.
In particular, the calculation of the level of fees charged by the Agency should be based on the principle of the service actually provided and should be related to specific medicinal products.
Zlasti mora izračun višine pristojbin, ki jih zaračunava Agencija, temeljiti na načelu dejansko zagotovljenih storitev in mora biti povezan s posameznimi zdravili.
The proportionality between the fees and the assessment related costs of each application, as well as the provision of the service requested, should also be ensured.
Prav tako je treba zagotoviti sorazmernost med pristojbinami ter stroški, ki so povezani z oceno vsake vloge, kot tudi zagotovitvijo pričakovane storitve.
Regulation (EC) No 726/2004 lays down provisions for new post-authorisation activities to be carried out by the Agency.
Uredba (ES) št. 726/2004 predpisuje določbe za nove dejavnosti po izdaji dovoljenja, ki jih mora izvajati Agencija.
These tasks include the recording of the actual marketing of medicinal products authorised in accordance with Community procedures, the maintenance of marketing authorisation dossiers and of the various databases managed by the Agency, as well as the continuous follow-up of the risk-benefit balance of authorised medicinal products.
Te naloge vključujejo registracijo dejanskega dajanja odobrenih zdravil v promet v skladu s postopki Skupnosti, vzdrževanje dokumentacije o dovoljenjih za promet in različnih baz podatkov Agencije ter stalno spremljanje razmerja med tveganjem in koristmi odobrenih zdravil.
In addition, it is necessary to reduce the Agency’s dependence on fees related to new applications.
Poleg tega bi bilo treba znižati odvisnost Agencije od pristojbin, povezanih z novimi vlogami.
The annual fee should therefore be increased by 10 % to accommodate those changes.
Da bi se ustrezno odzvali tem spremembam, bi se morala letna pristojbina povišati za 10 %.
New categories of fees have to be created to cover new, specific tasks now provided by the Agency, such as new types of scientific opinions related to a medicinal product.
Oblikovati je treba nove kategorije pristojbin, ki bodo pokrivale nove posebne naloge, ki jih sedaj zagotavlja Agencija, kot so na primer nove vrste znanstvenih mnenj o zdravilih.
The Management Board of the Agency should be competent to specify provisions necessary for the application of this Regulation, on a proposal from the Executive Director and following a favourable opinion from the Commission.
Upravni odbor Agencije bi moral imeti na predlog izvršnega direktorja in na podlagi pozitivnega mnenja Komisije pooblastila za podrobno opredelitev določb, ki so potrebne za uporabo te uredbe.
In particular, since the levels of fees laid down in this Regulation are set as maximum fees, the Management Board should establish, for certain services for which this is laid down in the Regulation, detailed classifications and lists of reduced fees.
Upravni odbor mora predvsem uvesti podrobne razvrstitve in sezname znižanih pristojbin za nekatere storitve, določene v tej uredbi, za katere so določene najvišje pristojbine.
The Executive Director should also keep the competence to decide, in exceptional circumstances, on reductions of the fees, in particular as regards certain cases related to specific medicinal products and where a reduction is necessary for imperative reasons of public or animal health.
Izvršni direktor bi moral prav tako obdržati pooblastila, da v izjemnih okoliščinah odloči o znižanju pristojbin, zlasti v določenih primerih, povezanih s posameznimi zdravili in kjer je znižanje potrebno iz nujnih razlogov javnega zdravja ter zdravja živali.
Likewise, the Executive Director should have the possibility to decide on exemptions from the obligation to pay a fee in the case of medicinal products for the treatment of rare diseases, for the treatment of diseases affecting minor animal species and for the addition of animal species in the case of the determination of maximum residue limits in accordance with the procedure laid down in Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin [6].
Prav tako mora izvršni direktor imeti možnost, da odloča o oprostitvah obveznosti plačila pristojbine za zdravila za zdravljenje redkih bolezni, za zdravljenje bolezni, ki prizadenejo manj številčne živalske vrste, in da odloča o dodatnih živalskih vrstah v primeru določitve najvišjih mejnih vrednosti ostankov v skladu s postopkom, določenim v Uredbi Sveta (EGS) št. 2377/90 z dne 26. junija 1990 o določitvi postopka Skupnosti za določanje najvišjih mejnih vrednosti ostankov zdravil za uporabo v veterinarski medicini v živilih živalskega izvora [6].
In accordance with Article 70(2) of Regulation (EC) No 726/2004, the circumstances under which small and medium-sized enterprises may pay reduced fees, defer payment of the fee or receive administrative assistance are not to be covered by this Regulation.
V skladu s členom 70(2) Uredbe (ES) št. 726/2004 se ta uredba ne nanaša na okoliščine, v katerih lahko mala in srednje velika podjetja plačajo znižane pristojbine, odložijo plačilo pristojbine ali prejmejo upravno pomoč.
In order to allow an immediate budgetisation, the fees should be due on the date of validation but should be payable within a certain number of days.
Da se omogoči takojšnja vključitev v proračun, morajo pristojbine zapasti na dan potrditve prejema vloge in biti plačane v določenem številu dni po tem.
Provisions should be laid down to report on the implementation of this Regulation after experience has been gained and to review, if necessary, the level of the fees.
Predvideti je treba določbe glede poročanja o uporabi te uredbe na osnovi pridobljenih izkušenj in, če je potrebno, pregledati višino pristojbin.
It is appropriate to include an indexation mechanism for automatically adjusting the fees in relation to official inflation rates indices.
Primerno je vključiti mehanizem indeksacije za avtomatično prilagajanje pristojbin glede na uradne inflacijske indekse.
For the sake of consistency, this Regulation should apply at the same time as the full entering into force of Regulation (EC) No 726/2004.
Zaradi usklajenosti bi bilo to uredbo treba začeti uporabljati hkrati z začetkom uporabe celotne Uredbe (ES) št. 726/2004.
It should not apply to valid applications pending at the time of its application.
Ne bi se je smelo uporabljati za veljavne vloge, ki so bile v trenutku sprejetja te uredbe še nerešene.
Regulation (EC) No 297/95 should therefore be amended accordingly,
Uredbo (ES) št. 297/95 je treba zato ustrezno spremeniti –
Regulation (EC) No 297/95 shall be amended as follows:
Uredba (ES) št. 297/95 se spremeni:
the second paragraph of Article 1 shall be replaced by the following:
Drugi odstavek člena 1 se nadomesti z naslednjim:
‘The amounts of these fees shall be laid down in euro.’;
„Zneski teh pristojbin se določijo v eurih.“;
‘Medicinal products for human use covered by the procedures laid down in Regulation (EC) No 726/2004(b) paragraph 1 is amended as follows:
„Zdravila za uporabo v humani medicini, ki so zajeta s postopki, določenimi v Uredbi (ES) št. 726/2004(b) odstavek 1 se spremeni:
in point (a) the first and second subparagraph shall be replaced by the following:
prvi in drugi pododstavek točke (a) se nadomestita z naslednjim:
‘A full fee of EUR 232000 shall apply for an application for a marketing authorisation supported by a full dossier. That fee shall cover a single strength associated with one pharmaceutical form and one presentation.
„Polna pristojbina za vlogo za pridobitev dovoljenja za promet z zdravilom, ki jo spremlja popolna dokumentacija, znaša 232000 EUR. Ta pristojbina krije eno samo jakost, povezano z eno farmacevtsko obliko in eno obliko pakiranja.
That increase shall cover one additional strength or pharmaceutical form and one presentation.’;
To povišanje zajema eno dodatno jakost ali farmacevtsko obliko in eno obliko pakiranja.“;
points (b) and (c) shall be replaced by the following:
točki (b) in (c) se nadomestita z naslednjim:
Reduced fee
Znižana pristojbina
A reduced fee of EUR 90000 shall apply to applications for a marketing authorisation pursuant to Article 10(1) and (3), and Article 10c of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
Znižana pristojbina v višini 90000 EUR se uporablja za vloge za pridobitev dovoljenja za promet z zdravilom v skladu s členi 10(1), 10(3) in 10c Direktive Evropskega parlamenta 2001/83/ES in Sveta z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v humani medicini.
That fee shall cover a single strength associated with one pharmaceutical form and one presentation.A specific reduced fee of EUR 150000 shall apply to applications for a marketing authorisation pursuant to Article 10(4) of Directive 2001/83/EC.
Ta pristojbina krije eno samo jakost, povezano z eno farmacevtsko obliko in eno obliko pakiranja.Posebna znižana pristojbina 150000 EUR se uporablja za vloge za pridobitev dovoljenja za promet v skladu s členom 10(4) Direktive 2001/83/ES.
That fee shall cover a single strength associated with one pharmaceutical form and one presentation.
Ta pristojbina krije eno samo jakost, povezano z eno farmacevtsko obliko in eno obliko pakiranja.
The reduced fees referred to in the first and second subparagraph shall be increased by EUR 9000 for each additional strength or pharmaceutical form submitted at the same time as the initial application for authorisation.
Znižane pristojbine iz prvega in drugega pododstavka se povišajo za 9000 EUR za vsako dodatno jakost oziroma farmacevtsko obliko, predloženo hkrati z osnovno vlogo za pridobitev dovoljenja.
That increase shall cover one additional strength or pharmaceutical form and one presentation.
To povišanje zajema eno dodatno jakost ali farmacevtsko obliko in eno obliko pakiranja.